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ABSTRACT: Fimbria-fornix lesions disrupt important parts of
serotonergic and noradrenergic hippocampal afferents and
elicit sprouting of sympathetic fibers from the superior cer-
vical ganglion. Since 5-hydroxytryptamine (5-HT) release
in the hippocampus is modulated by 5-HT1B auto- and a2-
heteroreceptors, we investigated whether such lesions may
alter these presynaptic mechanisms. Hippocampal slices of
sham-operated (SHAM) and fimbria-fornix–lesioned (LES)
rats (14 months after surgery) were preincubated with [3H]5-
HT, superfused continuously, and stimulated electrically us-
ing two stimulation conditions: either (a) 360 pulses 3 Hz,
or (b) 20 pulses 100 Hz (2 ms, 28 mA, 4 V/chamber). The
amount of [3H]5-HT taken up by slices from LES rats was
significantly reduced, whereas the evoked 5-HT release (in
percent of tissue-3H) was unchanged compared to that of
SHAM rats. The 5-HT1B agonist CP 93,129 or the a2-agonist
UK 14,304 reduced the evoked 5-HT release more potently in
slices from LES rats, but only using stimulation condition
(a), which permits inhibition by endogenously released
transmitters. In LES rats, the facilitatory effect of the 5-HT
antagonist metitepine was weaker, whereas that of the a2-
antagonist idazoxane was more pronounced than in SHAM
rats. In LES rats, hippocampal 5-HT content was reduced
to about 45% of SHAM levels, whereas that of noradrenaline
was increased by about 30% (high-performance liquid chro-
matography). We conclude: (1) despite LES-induced changes
in tissue levels of endogenous ligands, there is no down-
or upregulation of 5-HT1B-autoreceptors or a2-heterorecep-
tors on serotonergic neurons in the denervated rat hip-
pocampus. (2) The reduced endogenous autoinhibition
(by 5-HT) seems to be compensated for by an increased
heteroinhibition (by noradrenaline). © 1999 Elsevier Sci-
ence Inc.
KEY WORDS: Serotonin release, Sympathetic sprouting, CP
93,129, UK 14,304, Metitepine, Idazoxane.
INTRODUCTION
The release of 5-hydroxytryptamine (5-HT) and noradrenaline
(NA) in mammalian brain structures, including the hippocampus,
is modulated by presynaptic auto- and heteroreceptors (for reviews
see [27,29,30,58,60,61]). 5-HT autoreceptors have been identified
as 5-HT1B receptors in the rat hippocampus ([52], see also [27]),
and the a2-autoreceptor (at least in the rat cortex) has been clas-
sified as a2D-adrenoceptor (see [61]).
Interestingly, there are also well-documented interactions of
these two transmitter systems at the presynaptic level. For in-
stance, it has been shown that serotonergic axon terminals in the
central nervous system (CNS) of various species (including hu-
man) are endowed with inhibitory a2-adrenoceptors, which are
activated by endogenously released NA [21–24,28,46,51,55,59].
In the rat cortex, these a2-adrenoceptors belong to the a2D-subtype
[64]. In contrast, although 5-HT receptors are thought to be present
on noradrenergic neurons in peripheral tissues (see [30]), there are
conflicting data for the presence of 5-HT receptors on central
noradrenergic axon terminals: enhancement of NA release via
presynaptic 5-HT3 receptors has been suggested by one laboratory
[53], whereas other groups have shown that facilitatory effects of
5-HT3 agonists are mediated by blockade of a2-autoreceptors on
central noradrenergic neurons [2,56].
Among several other afferents, the hippocampal formation
receives prominent projections, both from the locus coeruleus and
the raphe´ nuclei in the brain stem (see [3]). Since these noradren-
ergic and serotonergic afferents profoundly affect the activity of
hippocampal neurons, any change in the release of NA and/or
5-HT from the axon terminals of these afferent fibers may also
affect hippocampal function. Therefore, it is the aim of the present
study to monitor changes in presynaptic 5-HT1B auto- and a2-
heteroreceptor function on serotonergic neurons in the hippocam-
pal formation of rats following an experimentally induced patho-
physiological situation, i.e., aspirative lesions of the fimbria fornix.
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Partial or extensive lesions of the septohippocampal pathways
are considered as one of the possible experimental models of
Alzheimer’s disease in animals (e.g., [12,19,40,41]). Such lesions
are known to induce a series of deficits, including severe and
lasting depletions of some hippocampal neurotransmitters and
related enzymes or metabolites (e.g., acetylcholine, choline acetyl-
transferase activity, 5-HT; [9,10,18,20,40,42,43,62,63]). Whereas
the markers of cholinergic and serotonergic innervation show poor
recovery over time, those of noradrenergic innervation are normal-
ized within several weeks and even largely overcompensated after
a few months (e.g. [14,39,50]). Part of this overcompensation is
due to the phenomenon of nonregenerative sprouting of sympa-
thetic fibers arising from the superior cervical ganglia (SCG).
Whereas these sympathetic fibers and their axon terminals are
normally confined to cerebral blood vessels, the choroid plexus
and the pineal gland [14,16,49], they begin to invade the hip-
pocampal parenchyma as a consequence of cholinergic denerva-
tion [14,15,25,26] and their protracted ingrowth seems inexhaust-
ible.
Although this sprouting reaction of sympathetic neurons has
been well-characterized neuroanatomically [14], there are only a
few—sometimes contradictory—behavioral studies (e.g. [4,13,17,
33,36]), some reports about electrophysiological approaches [6,44]
and several neuropharmacological investigations [5,31,32,34,35,
45,54] of this phenomenon. Interestingly, it has been shown that
sympathetic sprouting may also occur in the brains of patients with
Alzheimer’s disease [7]. Therefore, the functional consequences of
sympathetic fiber ingrowth into the hippocampus may also be of
clinical interest and hence, need further characterization, in par-
ticular at a more cellular level.
Recently, we studied some aspects of the modulation of the
evoked release of acetylcholine (ACh; [11]) and NA (unpublished
data) in hippocampal tissue of rats subsequent to septohippocam-
pal denervation. However, as concerns functional changes of
5-HT1B autoreceptors subsequent to (serotonergic) denervation, or
of a2-heteroreceptors on serotonergic axon terminals subsequent
to lesion-induced sympathetic sprouting, no investigation has been
undertaken so far. Therefore, the two main questions of the present
investigation are whether changes in the functions (a) of 5-HT
autoreceptors and (b) of a2-heteroreceptors on serotonergic neu-
rons can be detected in hippocampal tissue subsequent to fimbria-
fornix lesions. Our previous neurochemical studies [10,39] have
shown that following aspirative lesions of the fimbria-fornix, re-
ductions of 5-HT levels, or increases in NA concentrations, were
most dramatic in the dorsal and ventral parts of the hippocampus,
respectively. Therefore, experiments concerning 5-HT autorecep-
tor function were performed on slices from the dorsal hippocam-
pus, whereas for those concerning a2-heteroreceptor function,
slices of the ventral hippocampus were used.
MATERIALS AND METHODS
Chemicals and Drugs
Chemicals and drugs were obtained from the following sourc-
es: 5-[1,2-3H(N)]hydroxytryptamine creatinine sulfate ([3H]5-HT,
30.0 Ci/mmol) from NEN (Dreieich, Germany); 6-nitroquipazine
maleate, methiotepine mesylate (metitepine) from RBI, (Biotrend,
Ko¨ln, Germany). The following drugs were kindly provided by the
producers: 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrollo[3,2-b]pyrid-5-
one (CP 93,129) Pfizer, Karlsruhe, Germany; 5-bromo-6-(2-imi-
dazolin-2-ylamino)-quinoxaline tartrate (UK 14,304) Pfizer (Sand-
wich, Kent, UK); (6)idazoxane HCl, Reckitt & Colman;
(Kingston-upon-Hull, UK).
Subjects
The study used Long-Evans female rats (n 5 32) obtained
from R. Janvier (France). They were housed in Makrolon cages
(59 3 38 3 20 cm) in groups of five or six. For lesion surgeries,
they were isolated in smaller cages (42 3 26 3 15 cm) where they
were kept for 3 days after surgery. Food and water were available
ad lib. The colony room was maintained on a 12 h light:12 h dark
cycle (lights on at 0700) under controlled temperature (23 6 1°C).
All procedures involving animals and their care were conducted in
conformity with the international guidelines that are in compliance
with national and international laws and policies (Council directive
#87848, October 19, 1987, Ministe`re de l’Agriculture et de la
Foreˆt, Service Ve´te´rinaire de la Sante´ et de la Protection Animales;
permission #6212 to J-C. C. and #2108 to C. K.)
Fimbria-Fornix Lesions
All surgery was performed under aseptic conditions, using
pentobarbital anesthesia (40 mg/kg, intraperitoneally [i.p.]) after
an atropine sulfate injection (4 mg/kg, i.p., 10 min prior to the
injection of pentobarbital). At about 30 days of age, 16 fimbria-
fornix–lesioned rats (LES) received bilateral aspirative lesions as
described previously [10,39]. The control group (SHAM, n 5 16)
consisted of rats that were subjected to all surgical steps except
that no tissue was aspirated. Fifty-four to 60 weeks (14.5–15
months) after lesion surgery, the rats were sacrificed for superfu-
sion experiments.
Dissection of the Hippocampus and Neurochemical
Determinations
The rats were sacrificed by decapitation, their brains quickly
removed, both hippocampi were dissected free and divided into
two parts (ventral and dorsal half) and cut into 350-mm thick
transversal slices and suspended in modified Krebs Henseleit (KH)
buffer (for composition see below). From each part, about eight
slices were preincubated with [3H]5-HT as described below. The
remaining slices were washed in about 3 ml of isotonic phosphate
buffer (concentrations in mM: NaCl: 140; KCl: 3; Na2HPO4: 1.2;
NaH2PO4: 0.27; CaCl2: 1.2; pH 7.4) and homogenized in 1 ml
(each) of the same buffer in a Potter/Elvehjem glass/teflon homog-
enizer (8 strokes at 500 rpm). From this crude homogenate, a 20-ml
sample was used for measurement of protein [48]. Another 300-ml
sample was stored at 280°C until determination of ChAT activity,
as described previously [10,39].
A further 300-ml aliquot of the homogenate was mixed with
300 ml 0.2 N HClO4 (containing 250 mg Na2SO3 and 200 mg
disodium EDTA per liter) and stored at 280°C for high-perfor-
mance liquid chromatography (HPLC) measurements of mono-
amines. Separation was performed on a Spherisorb ODS2 (5-mm
pore size) reversed phase column (4.6 3 250 mm), the mobile
phase (0.7 ml/min, ESA pump) containing 75 mM NaH2PO4, 1.7
mM octane sulfonic acid (sodium salt), 20 mM EDTA, 100 ml
triethylamine and 10% acetonitrile (pH 3 with H3PO4). The
amount of NA, 5-HIAA, and 5-HT was determined using a Cou-
lochem II electrochemical detector (ESA; equipped with dual
porous graphite electrodes set at 275 and 1400 mV, respectively),
coupled to a Waters Baseline 810 chromatography workstation.
Under these conditions detection limit was less than 10 pg.
Accumulation of [3H]5-HT and Evoked Release of [3H]5-HT
The dorsal and ventral hippocampal slices selected for super-
fusion experiments were transferred into small Petri dishes con-
taining 2 ml KH buffer with [3H]5-HT (0.1 mM), and incubated for
45 min at 37°C under carbogen. The KH solution had the follow-
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ing composition (in mM): NaCl, 118; KCl, 4.8; CaCl2, 1.3;
MgSO4, 1.2; NaHCO3, 25; KH2PO4, 1.2; glucose, 11; ascorbic
acid, 0.57; Na2EDTA, 0.03; saturated with carbogen, pH adjusted
to 7.4. After incubation, 24 slices were transferred into superfusion
chambers (12 chambers per superfusion apparatus, 1 slice per
chamber) and superfused with oxygenated KH buffer (37°C) at a
rate of 0.6 ml/min. The superfusion medium was supplemented
routinely with 6-nitroquipazine (1 mM); in some experiments
additional drugs were present throughout superfusion, as indicated
in the legends of figures or tables. Fractions (4 min) to be measured
were collected from 45 min of superfusion onwards.
[3H]5-HT release was induced by up to four electrical field
stimulations after 57 min (S1), 85 min (S2), 113 min (S3), and 141
min (S4) of superfusion. Two different stimulation conditions were
used (see legends to Figures or Tables): (a) 360 rectangular pulses
at 3 Hz, 2 ms, 4 V/chamber, 27–30 mA, and (b) 20 pulses 100 Hz,
2 ms, 4 V/chamber, 27–30 mA). Drugs to be tested were added (in
concentrations increasing from S2 to S4) to the superfusion me-
dium of some chambers from 12 min before the corresponding
stimulation periods onward. At the end of the experiment (after
157 min of superfusion) the radioactivity of superfusate samples
and slices (dissolved in 500 ml Soluene 350, Packard, Frankfurt,
Germany) was determined by liquid scintillation counting. Calcu-
lation of both the spontaneous outflow and the stimulation-evoked
overflow of tritium was done as described previously [10]. The
effects of drugs added before S2, S3, or S4 were determined as the
ratios of the overflows evoked by the corresponding stimulation
periods (S2/S1; S3/S1; S4/S1) and compared to the appropriate
control ratios (no drug addition before S2, S3, and S4). Of the drugs
investigated, only idazoxane (1 and 10 mM) slightly increased the
spontaneous outflow of tritium by about 10% ( p , 0.05).
Statistical Analysis
As regards [3H]5-HT accumulation of the slices and the aver-
age amount of [3H]overflow evoked by S1, mean values 6 SEM
were obtained from the pooled single values of all rats subjected to
the same treatment (from each experiment up to six slices per rat
and hippocampal subregion). Concerning the effects of drugs on
electrically evoked [3H]overflow, the corresponding S2/S1 ratios of
all slices from rats with the same surgical and experimental treat-
ment were pooled. Statistical comparison of groups of treatment
was done using either analysis of variance (ANOVA) followed by
Bonferroni’s t-test or, where appropriate, by Student’s t-test.
RESULTS
Neurochemical Determinations
In order to quantify, at least approximately, the changes in the
density of cholinergic, noradrenergic, and serotonergic innervation
in hippocampal tissue caused by aspirative fimbria-fornix lesions,
several neurochemical markers were measured in the hippocampal
slices that were not used for superfusion experiments (Table 1).
Approximately 13.5–15 months after the lesion surgery, i.e., at the
time of the functional assays described below, we found that there
was a 50% and 35% reduction in ChAT activity in the dorsal and
ventral hippocampus, respectively. The NA content was increased
by about 30% in both parts, although—due to a high variability of
individual values—this increase was not statistically significant.
On the other hand, the contents of 5-HT- and 5-hydroxyindoleace-
tic acid (5-HIAA) were significantly reduced in both the dorsal and
ventral hippocampus. There was, however, no significant change
in the 5-HIAA/5-HT ratio (note that these ratios are calculated as
mean values from individual 5-HT and 5-HIAA values found for
each rat).
Electrically Evoked 5-HT Release: General Properties
Incubation of hippocampal slices with low concentrations of
[3H]5-HT is generally assumed to specifically label a pool of 5-HT
stored in vesicles of serotonergic axon terminals. In order to check
for possible false labeling of noradrenergic neurons (irrespective
of their origin), we incubated hippocampal slices (dorsal and
ventral parts) of two sham-operated and two lesioned rats with
[3H]5-HT (0.1 mM for 45 min) either in the absence of any drug
(controls) or in the presence of the preferential NA reuptake
blocker blocker (1)oxaprotiline (1 mM), or of the preferential
TABLE 1
NEUROCHEMICAL MARKERS IN DORSAL AND VENTRAL HIPPOCAMPUS
Neurochemical
Marker Measured
Dorsal Hippocampus Ventral Hippocampus
SHAM LES SHAM LES
ChAT activity 0.86 6 0.06 0.43 6 0.09 1.15 6 0.0711 0.75 6 0.081
(nmol/mg protein/min) (50%)** (65%)***
NA content 1.10 6 0.22 1.43 6 0.26 1.70 6 0.34 2.28 6 0.45
(ng/mg protein) (130%) (134%)
5-HT content 1.13 6 0.24 0.52 6 0.10 2.44 6 0.571 1.08 6 0.191
(ng/mg protein) (45%)* (44%)*
5-HIAA content 5.16 6 0.76 2.81 6 0.33 8.88 6 0.89111 5.27 6 0.5511
(ng/mg protein) (54%)** (59%)**
5-HIAA/5-HT ratio 9.70 6 2.49 8.60 6 1.45 4.65 6 0.48 7.22 6 1.22
SHAM, sham-operated; LES, Fimbria-Fornix lesioned; NA, noradrenaline; 5-HT, 5-hydroxytryptamine; 5-HIAA, 5-hy-
droxyindoleacetic acid.
Means 6 SEM values of neurochemical markers measured in (the remaining slices of) dorsal and ventral hippocampus of
SHAM (n 5 16) and LES (n 5 16) rats at about 13.5 to 15 months after lesion surgery. Numbers in parentheses express
the values from LES rats as a percentage of the corresponding values of SHAM rats.
Significant differences as compared to corresponding values from SHAM rats: *p , 0.05, **p , 0.01, ***p , 0.001;
significant differences as compared to values from the corresponding dorsal hippocampus: 1p , 0.05, 11p , 0.01,
111p , 0.001.
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5-HT reuptake blocker fluvoxamine (1 mM), or in the presence of
both drugs. Following incubation, all slices were washed exten-
sively and their [3H]content was determined by liquid scintillation
counting. It was found that the presence of (1)oxaprotiline had no
effect (105 6 6% of corresponding control) on the tissue [3H]con-
tent of the slices following incubation. In contrast, fluvoxamine
(37 6 2% of corresponding control), and the combination of both
reuptake inhibitors (35 6 2% of corresponding control), signifi-
cantly reduced [3H]5-HT accumulation of the slices (means from
24–32 slices each, per treatment). Moreover, there was no differ-
ence in these data when values from slices of sham-operated and
lesioned rats were compared.
Following preincubation with [3H]5-HT (in the absence of any
reuptake inhibitor), hippocampal slices were superfused continu-
ously with medium containing routinely the 5-HT reuptake blocker
6-nitroquipazine. During superfusion, release of transmitters in the
tissue was triggered by electrical field stimulation as exemplified
in Fig. 1A–D (a very similar figure can be drawn for the slices
from the ventral hippocampus) and detected as an increase of the
[3H]outflow from the slices (“evoked [3H]overflow”). Two stim-
ulation conditions were used in the present study: the first one (360
pulses, 3 Hz; Fig. 1A and 1B) allowing interaction of endog-
enously released neurotransmitters with exogenously added drugs,
and the second one (20 pulses, 100 Hz) avoiding a similar inter-
action ([57] see also Discussion). In order to verify that—under
stimulation conditions precluding autoinhibition—an autoinhibi-
tory tone of endogenous 5-HT (or of NA) was absent, we tested the
effect of the 5-HT antagonist metitepine (1 mM) (or the a2-
adrenoceptor antagonist idazoxane [1 mM]) using the 20-pulses–
100-Hz stimulation paradigm and found no significant facilitatory
effects (data not shown).
In Fig. 1A–D, the outflow of tritium from the tissue is always
expressed in percent of the content of tissue-3H of the correspond-
ing fraction. It appears from the figure that the evoked overflow of
FIG. 1. Example (n 5 6 slices, each) of baseline and evoked [3H]overflow (6 SEM) from slices (preincubated with tritiated 5-HT) of the dorsal
hippocampus of sham-operated (SHAM) and lesioned (LES) rats. Following preincubation with [3H]5-HT, the slices were superfused (0.4 ml/min)
continuously in the presence of 6-nitroquipazine (1 mM); in C and D the superfusion medium contained, in addition, idazoxane (0.1 mM). During
superfusion, electrical field stimulations were performed after 57 min (S1), 85 min (S2), 113 min (S3), and 141 min (S4) of superfusion, as indicated by the
black bars. In A and B, the stimulation parameters were: 360 pulses, 3 Hz (2 ms, 27–30 mA), whereas in C and D, only 20 pulses at 100 Hz (2 ms, 27–30
mA) were applied. The [3H] outflow from the slices during superfusion is shown as a percentage of tissue-3H in each fraction per 4-min collection period
(“fractional rate of 3H-efflux”). The average electrically evoked overflow at S1 of all slices superfused and stimulated under the conditions shown in Fig.
1A–D is given in Tables 2 and 3.
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[3H] is unchanged in lesioned animals as compared to sham-
operated ones: this is also underlined by statistical comparison (see
Tables 2 and 3) of all S1-values (in percent of tissue-3H) from all
rats studied. However, when the evoked overflow is evaluated in
absolute terms (i.e., in nCi [3H]overflow/slice), significantly lower
values are found in lesioned rats. Similarly, in comparison to
values from SHAM rats, also the tissue-loading of hippocampal
slices of LES rats with [3H]5-HT was significantly lower in slices
from both the dorsal and ventral hippocampus. Moreover, by
comparing the percent values given in Tables 2 and 3, two obser-
vations can be made: first, the reduction of the evoked [3H]
overflow in LES rats seems to be due solely to the lower tissue
loading with [3H]5-HT. Second, the lesion-induced reductions of
[3H]5-HT tissue loading and evoked overflow (nCi/slice) are sig-
TABLE 2
ACCUMULATION AND EVOKED OVERFLOW OF [3H]5-HT IN RAT HIPPOCAMPUS SLICES
(EXPERIMENTS USING STIMULATION WITH 360 PULSES AT 3 HZ)
Parameter Measured
Dorsal Hippocampus Ventral Hippocampus
SHAM
(n 5 63)
LES
(n 5 54)
SHAM
(n 5 65)
LES
(n 5 60)
Tissue loading with [3H]5-HT (pmol/slice) 1.44 6 0.05 0.61 6 0.03 2.04 6 0.06 1.61 6 0.05
(42%) (79%)
(***) (111) (111, ***)
Evoked overflow of [3H] at S1 (% of tissue-3H) 5.97 6 0.19 6.39 6 0.23 4.49 6 0.12 4.84 6 0.19
(107%) (108%)(111) (111)
Evoked overflow of [3H] at S1 (nCi/slice) 2.57 6 0.15 1.10 6 0.06 2.65 6 0.12 2.21 6 0.09
(43%) (83%)
(***) (111, **)
SHAM, sham-operated; LES, fimbria-fornix lesioned; n, number of slices/group of rats; 5-HT, 5-hydroxytryptamine.
Slices of the dorsal and ventral hippocampus of SHAM (n 5 11) and LES (n 5 11) rats were incubated with [3H]5-HT for 45 min,
superfused in the presence of 6-nitroquipazine (1 mM) and electrically stimulated (360 pulses, 3 Hz) as described in Methods and shown
in Fig. 1 A,B. The tissue content of [3H] at the beginning of the collection period and the electrically evoked overflow of tritium at the
first stimulation period (S1) are shown. Both the relative amount of [3H]overflow at S1 (in % of the tissue content of [3H]5-HT before
the stimulation period), as well as the absolute amount (in nCi/slice) are presented.
Values in parentheses represent values from LES rats expressed as a percentage of the corresponding values from SHAM rats.
Significance of differences to corresponding values from SHAM rats: *p , 0.05, **p , 0.01, ***p , 0.001; significance of
differences to values from corresponding dorsal hippocampus: 1p , 0.05, 11p , 0.01, 111p , 0.001.
TABLE 3
ACCUMLUATION AND EVOKED OVERFLOW OF [3H]5-HT IN RAT HIPPOCAMPUS SLICES
(EXPERIMENTS USING STIMULATION WITH 20 PULSES AT 100 HZ)
Parameter Measured
Dorsal Hippocampus Ventral Hippocampus
SHAM
(n 5 30)
LES
(n 5 30)
SHAM
(n 5 30)
LES
(n 5 30)
Tissue loading with [3H]5-HT (pmol/slice) 1.77 6 0.05 1.15 6 0.13 2.24 6 0.09 1.68 6 0.06
(65%) (75%)
(***) (***)
Evoked overflow of [3H] at S1 (% of tissue-3H) 1.74 6 0.05 1.48 6 0.08 1.80 6 0.08 1.75 6 0.06
(85%) (97%)
(**)
Evoked overflow of [3H] at S1 (nCi/slice) 0.89 6 0.03 0.54 6 0.07 1.16 6 0.07 0.85 6 0.04
(61%) (73%)
(***) (***)
SHAM, sham-operated; LES, Fimbria-Fornix lesioned; n, number of slices/group of rats; 5-HT, 5-hydroxytryptamine.
Slices of the dorsal and ventral hippocampus of SHAM (n 5 5) and LES (n 5 5) rats were incubated with [3H]5-HT for 45 min,
superfused in the presence of 6-nitroquipazine (1 mM) and either idazoxane (0.1 mM; dorsal hippocampus) or metitepine (0.1 mM; ventral
hippocampus), and electrically stimulated (20 pulses, 100 Hz) as described in Methods and shown in Fig. 1C and 1D. The tissue content
of [3H] at the beginning of the collection period and the electrically evoked overflow of tritium at the first stimulation period (S1) are
shown. Both the relative amount of [3H]overflow at S1 (in % of the tissue content of [3H]5-HT before the stimulation period), as well
as the absolute amount (in nCi/slice) are presented.
Values in parentheses represent LES values expressed as a percentage of the corresponding values in SHAM rats.
Significancy of differences to corresponding values from SHAM rats: *p , 0.05, **p , 0.01, ***p , 0.001.
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nificantly larger in the dorsal than in the ventral hippocampus (see
Table 2). It should also be noticed that similar (dorsal vs. ventral)
comparisons in Table 3, or comparisons of absolute values in
Table 3 with those in Table 2 are not worthwhile, as different drug
combinations were present throughout superfusion.
Effects of 5-HT Agonists and Antagonists (Dorsal Hippocampus)
Modulation of the evoked 5-HT release via 5-HT1B autorecep-
tors was studied in slices of the dorsal hippocampus only. As
shown in Fig. 2A,B, the effect of the 5-HT1B agonist CP 93,129
was studied on these slices (following preincubation with [3H]5-
HT) under the two stimulation conditions depicted already in Fig.
1A–D. Addition of CP 93,129 to the superfusion medium in
increasing concentrations before S2, S3, or S4 led to significant
inhibition of the evoked [3H]overflow. From Fig. 2, it is evident
that CP 93,129 was significantly more potent in hippocampal slices
from LES than from SHAM rats, but only when 360 pulses at 3 Hz
(Fig. 2A) were applied. No difference in the inhibitory potency
was observed when the [3H]overflow was induced by 20 pulses at
100 Hz (Fig. 2B).
The effect of the (nonselective) 5-HT antagonist metitepine is
shown in Fig. 3. Using 360 pulses and 3 Hz as stimulation
parameters, metitepine (0.1–10 mM), as expected, significantly
enhanced the evoked [3H]overflow from hippocampal slices (pre-
incubated with [3H]5-HT) of both SHAM and LES rats, although
the effect was significantly larger in slices from SHAM rats.
In order to show that the effect of CP 93,129 was due to 5-HT
receptor stimulation, we also performed experiments in which both
CP 93,129 (1 mM) and metitepine (10 mM) were present during
stimulation (360 pulses, 3 Hz). In both SHAM and LES rats the
inhibitory effects of CP 93,129 were significantly reduced by the
simultaneous presence of metitepine (data not shown).
Effects of a2-Adrenoceptor Agonists and Antagonists (Ventral
Hippocampus)
Modulation of the evoked 5-HT release via a2-heteroreceptors
on serotonergic axon terminals was studied in slices of the ventral
hippocampus only. As shown in Fig. 4A,B, the effect of the
a2-adrenoceptor agonist UK 14,304 was studied on these slices
(following preincubation with [3H]5-HT) under the two stimula-
tion conditions depicted in Fig. 1A–D. Addition of UK 14,304 to
the superfusion medium in increasing concentrations before S2, S3,
or S4 led to a significant inhibition of the evoked [3H]overflow.
From Fig. 4, it is evident, that UK 14,304 was significantly more
FIG. 2. Electrically evoked 5-HT release from slices of the dorsal hippocampus of rats: effects of fimbria-fornix lesions on the inhibitory action of the
5-HT1B agonist CP 93,129. Following preincubation with [3H]5-HT, the hippocampal slices of sham-operated (SHAM) and lesioned (LES) rats were
superfused either in the presence of 6-nitroquipazine (1 mM) alone (A) or in the additional presence of idazoxane (0.1 mM, B) throughout. During
superfusion, up to four periods of electrical field stimulations (S1 to S4) were applied as shown in Fig. 1 A–D, i.e., either at 360 pulses 3 Hz (A), or at 20
pulses 100 Hz (B). The 5-HT1B agonist CP 93,129 was added (in concentrations increasing from S2 to S4, as shown on the abscissa) to the superfusion
medium from 12 min before the corresponding stimulation period onward. The effects of CP 93,129 are expressed at the ratios Sn/S1 of the evoked
[3H]overflows induced by the corresponding stimulation period. These ratios were normalized by calculating the % of control values of the corresponding
control Sn/S1-ratios (control 5 no drug addition before Sn). At all concentrations studied, CP 93,129 significantly (at least p , 0.01) inhibited the evoked
overflow of [3H]. Significance of differences between values from SHAM or LES rats: K p , 0.05; n 5 number of hippocampal slices from n 5 5–6
SHAM and n 5 5–6 LES rats.
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potent in hippocampal slices from LES than from SHAM rats, but
only when 360 pulses at 3 Hz (Fig. 4A) were applied. No differ-
ence in the inhibitory potency was observed when the [3H]over-
flow was induced by 20 pulses at 100 Hz (Fig. 4B).
The effect of the a2-adrenoceptor antagonist idazoxane is shown
in Fig. 5. Using 360 pulses and 3 Hz as stimulation parameters
idazoxane (0.1–10 mM), as expected, significantly enhanced the
evoked [3H]overflow from hippocampal slices (preincubated with
[3H]5-HT) of both SHAM and LES rats. In contrast to the effects
of the 5-HT antagonist metitepine (see Fig. 3), however, idazoxane
was significantly more potent in LES than in SHAM rats.
In order to show that the effect of UK 14,304 was due to a2-
adrenoceptor stimulation, we also performed experiments in which
both UK 14,304 (1 mM) and idazoxane (10 mM) were present
during stimulation (360 pulses, 3 Hz). In both SHAM and LES
rats, the inhibitory effects of CP 93,129 were completely antago-
nized by simultaneous presence of idazoxane (data not shown).
DISCUSSION
Neurochemical Effects of Fimbria-Fornix Lesions
Table 1 shows that fimbria-fornix lesions induced approxi-
mately 50% reduction of cholinergic and serotonergic markers in
the dorsal hippocampus 14 month after lesion surgery. Remark-
ably, these changes were smaller than those found in earlier studies
[10,39], and this was also observed as to the increase in NA tissue
levels induced by the lesions. Some differences in the preparation
of the samples used for neurochemical determinations might ac-
count for these differences. In contrast with our previous studies,
the samples were not prepared from freshly dissected tissue, but
from slices not used for superfusion, and which were washed with
homogenization buffer before being used. However, our data also
seem to indicate that the lesions in the present study might have
been less extensive than in our former experiments. Another con-
clusion that can be drawn from the data of Table 1 is that in both
SHAM and LES rats, the relative density of cholinergic, seroto-
nergic, and noradrenergic markers (and hence the corresponding
innervations) was higher in the ventral as compared to the dorsal
regions of the hippocampus. This observation is in agreement with
our earlier investigations [10,39] and data from the literature (e.g.,
[37]).
Effects of Fimbria-Fornix Lesions on Accumulation and Evoked
Overflow of [3H]5-HT
Incubation of hippocampal slices with low concentrations of
[3H]5-HT leads to a preferential labeling of transmitter stores in
serotonergic neurons (and not in noradrenergic neurons) as shown
by accumulation experiments in the presence of preferential block-
ers for serotonergic [fluvoxamine] and noradrenergic [(1)oxapro-
tiline] reuptake carriers. The fact that still about 35% of tissue
labeling was insensitive to both reuptake inhibitors might by due to
an amount of [3H]5-HT unspecifically (or specifically) bound to
the tissue.
Most probably due to this “unspecific” part of labeling of the
tissue, it is also clear that the values for “tissue loading with
[3H]5-HT” in Tables 2 and 3 cannot be directly compared with the
values of “5-HT content” in Table 1, although both parameters are,
in one way or another, linked to the density of serotonergic
innervation of the tissue. Moreover, the absolute values of the data
from Tables 2 and 3 cannot be compared directly because (a)
different stimulation conditions were used and (b) different drug
combinations were present throughout superfusion. Nevertheless,
by rough comparison of the tables the following conclusions are
supported by the data in the tables.
First, the density of serotonergic innervation is higher in the
ventral than in the dorsal part of the hippocampus (compare
absolute values for “5-HT content” [Table 1], or for “tissue loading
with [3H]5-HT” [Table 2 or 3]); this statement is also supported by
data from the literature (e.g., [37]).
Second, the effect of the fimbria-fornix lesion on the density of
serotonergic axon terminals seems to be more prominent in the
dorsal than in the ventral hippocampus (compare the percent
changes in parentheses in Tables 2 and 3). Although this observa-
tion is not supported by the “5-HT-content” values in Table 1, it is
in agreement with the literature and our previous studies (for a
review, see [12]).
Third, the electrically evoked overflow of [3H], which was
Ca21-dependent and tetrodotoxin-sensitive (data not shown) and,
therefore, has been thought to reflect action potential-evoked exo-
cytotic release of 5-HT (see for instance [29]), was reduced by the
lesion to about the same extent as the loading of tissue with
[3H]5-HT (cf. Tables 2 and 3). Consequently, if the evoked 5-HT
release of lesioned rats was expressed in percent of tissue-3H (cf.
Tables 2 and 3), no difference was observed as compared to
sham-operated rats; this observation indicates that in LES rats,
most probably the amount of transmitter released per (remaining)
axon terminal was the same as in SHAM rats: in other words, there
FIG. 3. Electrically evoked 5-HT release from slices of the dorsal hip-
pocampus of rats: effects of fimbria-fornix lesions on the facilitatory action
of the 5-HT receptor antagonist metitepine. Following preincubation with
[3H]5-HT, the hippocampal slices of sham-operated (SHAM) and lesioned
(LES) rats were superfused in the presence of 6-nitroquipazine (1 mM).
During superfusion four periods of electrical field stimulation (S1 to S4)
were applied as shown in Fig. 1A, B at 360 pulses 3 Hz. The 5-HT
antagonist metitepine was added (in concentrations increasing from S2 to
S4, as shown on the abscissa) to the superfusion medium from 12 min
before the corresponding stimulation period onward. The effects of me-
titepine are expressed at the ratios Sn/S1 of the evoked [3H]overflows
induced by the corresponding stimulation periods; these ratios were nor-
malized by calculating the % of control values of the corresponding control
Sn/S1-ratios (control 5 no drug addition before Sn). Significance of facili-
tatory effects of metitepine as compared to control values: ***p , 0.001;
**p , 0.01. Significance of differences between values from SHAM or
LES rats: G p , 0.05; n 5 number of hippocampal slices from n 5 6
SHAM and n 5 6 LES rats.
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was apparently no difference in the modulation of 5-HT release
from the spared axon terminals.
Fourth, although a direct comparison of the overflow evoked by
the two stimulation conditions was not possible (due to the pres-
ence of different drugs throughout superfusion), it is evident from
the data that stimulation with 360 pulses 3 Hz is subject to
inhibition by endogenously released compounds: the overflow
evoked per pulse was only 0.017% of tissue [3H] as compared to
0.087% using the “20-pulses-100-Hz” stimulation paradigm.
Lesion-Induced Effects of 5-HT1B Autoreceptor Function
The first main question of the present study was, whether
changes in the function of 5-HT autoreceptors could be observed
as a consequence of the serotonergic denervation of the hippocam-
pus. The present data indicate that there is no increase or decrease
in the sensitivity of 5-HT1B autoreceptors: although the preferen-
tial 5-HT1B receptor agonist CP 93,129 (see [38]) seems to be
significantly more potent under stimulation conditions, permitting
autoinhibition by ongoing release of endogenous 5-HT (360
pulses, 3 Hz, Fig. 2A), this higher sensitivity is not detectable
when the second stimulation paradigm (20 pulses, 100 Hz) is used
(Fig. 2B). With the latter paradigm, there is no or only negligible
autoinhibition because of both a much shorter delay between the
electrical pulses and a smaller number of pulses [57]. Hence, the
higher sensitivity of the autoreceptor observed in Fig. 2A seems to
be due mainly to a concentration of endogenous 5-HT which, in
the vicinity of the autoreceptors (“biophase concentration of
5-HT”) of the spared serotonergic axon terminals, was reduced as
a consequence of the lesions. As the endogenous neurotransmitter
(5-HT) is able to compete with the exogenous agonist (CP 93,129),
there is only an apparent higher sensitivity of the autoreceptor
toward the exogenous agonist. This conclusion is also supported
by the observation that the facilitatory effect of the nonselective
5-HT antagonist metitepine (see [38]) was significantly less pro-
nounced in hippocampal slices of LES rats than in those of SHAM
rats (Fig. 3).
Which consequences should be expected from these findings
for the situation in vivo? Since there is an apparent lesion-induced
loss in the “biophase concentration” of 5-HT near the autoreceptor,
the feedback inhibition of 5-HT release via activation of the
autoreceptor should be diminished, i.e., the 5-HT release of the
remaining serotonergic axon terminals should be increased. How-
ever, as already discussed above, the amount of 5-HT released per
serotonergic axon terminal seems to be unaffected by the lesion.
FIG. 4. Electrically evoked 5-HT release from slices of the ventral hippocampus of rats: effects of fimbria-fornix lesions on the inhibitory action of the
a2-adrenoceptor agonist UK 14,304. Following preincubation with [3H]5-HT, the hippocampal slices of sham-operated (SHAM) and lesioned (LES) rats
were superfused either in the presence of 6-nitroquipazine (1 mM) alone (A) or in the additional presence of metitepine (0.1 mM, B) throughout. During
superfusion up to four periods of electrical field stimulation (S1 to S4) were applied as shown in Fig. 1A–D, i.e., either at 360 pulses 3 Hz (A), or at 20
pulses 100 Hz (B). The a2-adrenoceptor agonist UK 14,304 was added (in concentrations increasing from S2 to S4, as shown on the abscissa) to the
superfusion medium from 12 min before the corresponding stimulation period onward. The effects of UK 14,304 are expressed at the ratios Sn/S1 of the
evoked [3H]overflows induced by the corresponding stimulation periods; these ratios were normalized by calculating the % of control values of the
corresponding control Sn/S1-ratios (control 5 no drug addition before Sn). At all concentrations studied UK 14,304 significantly (at least p , 0.01)
inhibited the evoked overflow of [3H]. Significance of differences between values from SHAM or LES rats: K p , 0.05; n 5 number of hippocampal
slices from n 5 5–6 SHAM and n 5 5–6 LES rats.
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Hence, additional presynaptic effects (see below) have to be pos-
tulated.
Lesion-Induced Effects on a2-Heteroreceptor Function
Our present results (Fig. 4A,B) clearly support the well-known
and potent a2-adrenoceptor-(i.e., heteroreceptor-) mediated control
of 5-HT release in the rat hippocampus (see [30]). Moreover, the
present observations show that, similar to what we found for the
5-HT1B autoreceptors, the sensitivity of a2-heteroreceptors on
serotonergic neurons also seems to be unaffected by fimbria-fornix
lesions. Using stimulation conditions (20 pulses, 100 Hz) that
preclude the action of endogenously released compounds, the
a2-adrenoceptor agonist UK 14,304 [8] was as efficient in lesioned
as in sham-operated rats (Fig. 4B).
Furthermore, as expected from the phenomenon of sympathetic
sprouting (see Introduction and the data of Table 1), the “biophase
concentration” of NA in the vicinity of the a2-heteroreceptor on
serotonergic axon terminals seems to be increased by the lesion:
the preferential a2-adrenoceptor antagonist idazoxane enhanced
the evoked 5-HT release more potently in LES than in SHAM rats
(Fig. 5). Interestingly, however, and in striking contrast with the
observations made in the presence of 5-HT autoreceptor agonists
and antagonists, the selective a2-adrenoceptor agonist UK 14,304
was more potent in LES than in SHAM rats under stimulation
conditions (360 pulses, 3 Hz) allowing the action of endogenously
released agonists (Fig. 4A). From the higher “biophase concentra-
tion” of endogenous NA (see above) it was expected that UK
14,304 would be less potent in LES than in SHAM rats.
Two possible explanations may account for this paradoxical
phenomenon. First, it has been shown that 5-HT itself has agonis-
tic properties at the a2-adrenoceptor [2]: therefore, it might be that
the increase of the “biophase concentration” of NA at the a2-
heteroreceptor was counteracted by the decrease of that of 5-HT at
the same receptor. Second, since the signal transduction pathways
of 5-HT1B- and a2-receptors may involve common steps, for
instance the same pool of G-proteins in the axon terminal mem-
brane, it may be that—due to the lesion-induced reduction of
5-HT1B receptor activation—the efficacy of a2-adrenoceptor sig-
nal transduction is increased and that this increase is only partially
compensated for by higher endogenous NA levels. It should be
noted that interactions of presynaptic receptors on the level of
signal transduction pathways have been observed previously for
other neurotransmitter systems (e.g., [1,47]).
As 5-HT1B autoreceptor-mediated inhibition of 5-HT release is
less pronounced in lesioned rats, whereas a2-heteroreceptor-me-
diated inhibition seems to be increased, it may be speculated that
sprouting-induced elevations of NA biophase concentrations partly
compensate for the reduction of the feedback autoinhibitory mech-
anism. This assumption is supported by the finding (see above and
Table 2) that in hippocampal slices of lesioned rats the same
amount of 5-HT per remaining serotonergic fibers seems to be
released.
General Conclusions
In the present investigation, for the first time possible changes
in the function of 5-HT1B auto- and a2-heteroreceptors at seroto-
nergic axon terminals were studied under conditions in which—
due to fimbria/fornix lesions—the concentrations of the endoge-
nous transmitters 5-HT and NA at these receptors were changed
for several months. Since similar changes also occur in the course
of neurodegenerative diseases, like Alzheimer’s disease (see In-
troduction), our observations may also be of clinical interest.
We found that the absolute amount of 5-HT released in the
hippocampus of rats with fimbria/fornix lesions was significantly
smaller than that of the corresponding sham-operated rats, most
probably due to the reduction of serotonergic fibers in the lesioned
tissue. Despite this fact, the modulation of release of 5-HT from
each of the remaining serotonergic axon terminals seemed to be
unaffected: no down-, or upregulation of the number or the sen-
sitivity of presynaptic 5-HT1B-, or a2-receptors, respectively, was
detectable under our experimental conditions. As both receptor
types, however, exert an inhibitory action on 5-HT release it is
possible that in vivo, a lesion-induced reduction of the autoinhibi-
tory tone of endogenous 5-HT is (at least partially) compensated
for by a sprouting-induced noradrenergic tone on serotonergic
axon terminals. To our knowledge, this is the first time that a
possible compensatory role of the sympathetic sprouting phenom-
enon has been suggested at a more cellular level.
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FIG. 5. Electrically evoked 5-HT release from slices of the ventral hip-
pocampus of rats: effects of fimbria-fornix lesions on the facilitatory action
of the a2-adrenoceptor antagonist idazoxane. Following preincubation with
[3H]5-HT, the hippocampal slices of sham-operated (SHAM) and lesioned
(LES) rats were superfused in the presence of 6-nitroquipazine (1 mM).
During superfusion four periods of electrical field stimulation (S1 to S4)
were applied as shown in Fig. 1A, B at 360 pulses 3 Hz. The a2-
adrenoceptor antagonist idazoxane was added (in concentrations increasing
from S2 to S4, as shown on the abscissa) to the superfusion medium from
12 min before the corresponding stimulation period onward. The effects of
idazoxane are expressed at the ratios Sn/S1 of the evoked [3H]overflows
induced by the corresponding stimulation periods; these ratios were nor-
malized by calculating the % of control values of the corresponding control
Sn/S1-ratios (control 5 no drug addition before Sn). Significance of facili-
tatory effects of idazoxane as compared to control values: *p , 0.05,
**p , 0.01, ***p , 0.001; Significance of differences between values
from SHAM or LES rats: G p , 0.05, GGG p , 0.001; n 5 number
of hippocampal slices from n 5 6 SHAM and n 5 6 LES rats.
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